Patterns of inflammation and the use of reversibility testing in smokers with airway complaints by Chavannes, Niels H et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Pulmonary Medicine
Open Access Research article
Patterns of inflammation and the use of reversibility testing in 
smokers with airway complaints
Niels H Chavannes*1, Juanita HJ Vernooy2, Tjard RJ Schermer3, 
Jan A Jacobs4, Mieke A Dentener2, Chris van Weel3, Onno CP van Schayck1 
and Emiel FM Wouters2
Address: 1Department of General Practice, Caphri Research Institute, Maastricht University, The Netherlands, 2Department of Respiratory 
Medicine, University Hospital Maastricht, The Netherlands, 3Department of General Practice/Family Medicine, Radboud University Nijmegen MC, 
The Netherlands and 4Department of Medical Microbiology, University Hospital Maastricht, The Netherlands
Email: Niels H Chavannes* - niels.chavannes@hag.unimaas.nl; Juanita HJ Vernooy - j.vernooy@pul.unimaas.nl; 
Tjard RJ Schermer - t.schermer@hag.umcn.nl; Jan A Jacobs - jja@lmib.azm.nl; Mieke A Dentener - mieke.dentener@pul.unimaas.nl; Chris van 
Weel - c.vanweel@hag.umcn.nl; Onno CP van Schayck - onno.vanschayck@hag.unimaas.nl; Emiel FM Wouters - e.wouters@lung.azm.nl
* Corresponding author    
Abstract
Background: Although both smoking and respiratory complaints are very common, tools to
improve diagnostic accuracy are scarce in primary care. This study aimed to reveal what
inflammatory patterns prevail in clinically established diagnosis groups, and what factors are
associated with eosinophilia.
Method: Induced sputum and blood plasma of 59 primary care patients with COPD (n = 17),
asthma (n = 11), chronic bronchitis (CB, n = 14) and smokers with no respiratory complaints
('healthy smokers', n = 17) were collected, as well as lung function, smoking history and clinical
work-up. Patterns of inflammatory markers per clinical diagnosis and factors associated with
eosinophilia were analyzed by multiple regression analyses, the differences expressed in odds ratios
(OR) with 95% confidence intervals.
Results: Multivariately, COPD was significantly associated with raised plasma-LBP (OR 1.2 [1.04–
1.37]) and sTNF-R55 in sputum (OR 1.01 [1.001–1.01]), while HS expressed significantly lowered
plasma-LBP (OR 0.8 [0.72–0.95]). Asthma was characterized by higher sputum eosinophilic counts
(OR 1.3 [1.05–1.54]), while CB showed a significantly higher proportion of sputum lymphocytic
counts (OR 1.5 [1.12–1.9]). Sputum eosinophilia was significantly associated with reversibility after
adjusting for smoking, lung function, age, gender and allergy.
Conclusion: Patterns of inflammatory markers in a panel of blood plasma and sputum cells and
mediators were discernable in clinical diagnosis groups of respiratory disease. COPD and so-called
healthy smokers showed consistent opposite associations with plasma LBP, while chronic
bronchitics showed relatively predominant lymphocytic inflammation compared to other diagnosis
groups. Only sputum eosinophilia remained significantly associated with reversibility across the
spectrum of respiratory disease in smokers with airway complaints.
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Background
Smoking causes chronic airway complaints in a significant
proportion of the population [1]. The primary care physi-
cian and respiratory nurse specialist are generally the first
to assess patients with a chronic cough, complaints of dys-
pnea or sputum production [2]. Ideally, common causes
like COPD and asthma are differentiated by spirometry
with reversibility testing, performed and interpreted by
sufficiently trained staff [3,4].
Sputum induction is a valid and noninvasive method to
assess airway inflammation, which is Patients with COPD
[5,6]There is evidence of different cellular and cytokine
activation in induced sputum from smoking compared
with nonsmoking asthmatics; a positive relationship is
apparent between smoking history, neutrophilic airway
inflammation and deteriorating lung function in smoking
asthmatics [7]. In mild asthmatics, but also in other respi-
ratory patients, sputum, bronchoalveolar lavage and
blood measure different compartments of inflammation
[8]. The proportion of eosinophils in sputum is a more
accurate marker of asthmatic airway inflammation than
the proportions of blood eosinophils [9], suggesting a
predominantly local systemic inflammatory process of
lung tissue.
Patients with COP show significantly higher percentages
of neutrophils and levels of soluble TNF receptor p55
(sTNF-R55) and the chemokine interleukin IL-8 in spu-
tum as compared with control subjects [10]. Both neu-
trophils and eosinophils seem to be activated by IL-8
[11,12], which seems to be closely related with the degree
of airflow obstruction [13]. In the circulation, increased
levels of inflammatory markers such as lipopolysaccha-
ride binding protein (LBP) and sTNF-R55 have been
reported [14].
We studied the relation between patterns of inflammation
and clinical diagnosis in primary care patients. By careful
history taking (symptoms, smoking behaviour, atopic his-
tory) and measuring lung function including reversibility
in smoking patients with respiratory complaints, we dis-
tinguished four clinical diagnosis groups: COPD (accord-
ing to GOLD [1]), asthma, chronic bronchitis (GOLD 0)
and a control group of 'healthy smokers' (no respiratory
symptoms, no obstruction). Aim of the study was not to
change or confirm these clinical diagnoses, but to reveal
any specific inflammatory patterns underlying disease
groups. We also tested what factors were associated with
eosinophilia, a possible target for treatment.
Methods
Patient selection
The COOPT-study (COPD On Primary Care Treatment)
recruited a heterogeneous group of (current or past)
smokers with mild to moderate COPD and chronic bron-
chitis from 46 general practices in the Netherlands [15].
Reversibility was not an exclusion criterion, but any his-
tory of atopy, eczema or asthma was. Patients with an
FEV1 between 40–88% of predicted values were included;
mean post-BD FEV1 was 66% of predicted value (ranging
from GOLD 0 to GOLD 3). A subgroup of the COOPT-
population underwent sputum induction at the lung
function laboratory of University Hospital Maastricht;
only those in whom sputum induction was successful
were included in analyses. In addition, we recruited smok-
ing control patients with asthma features (atopy, eczema,
previous recurrent episodes of wheezing, breathlessness,
chest tightness, and/or cough and variable airflow
obstruction to inhaled salbutamol) and smokers without
respiratory complaints ('healthy smokers') from general
practices not taking part in the COOPT-study, who subse-
quently also underwent sputum induction. Respiratory
symptoms, smoking behaviour, atopic features, careful
clinical history taking, and lung function measurements
including reversibility determined the diagnostic category
into which subjects were classified, analogue to earlier
studies [10,14]. Patients with COPD thus had an absence
of atopic features, but a smoking history of at least 15
packyears and a persistent obstruction, while patients
with asthma had an atopic history and a variable obstruc-
tion, with a recorded reversibility >10%. Chronic bron-
chitics had chronic respiratory complaints for at least 3
months during the past two years but no obstruction,
while 'healthy smokers' had a considerable smoking his-
tory but no chronic respiratory complaints.
During the recruiting phase, considerable effort was put
into age matching, since age has been shown to affect spu-
tum induction results [15]. Exclusion criterion was any
inhaled or oral corticosteroid use in past six weeks, since
this is known to possibly influence sputum induction
results and underlying systemic inflammatory patterns
[18,19]. Furthermore, increased respiratory complaints or
signs of respiratory tract infection during four weeks pre-
ceding the study was considered a criterion for exclusion.
The control subjects lived in the same geographical area as
the patient population. The study protocol was approved
by the Medical Ethics Committee at the University Hospi-
tal Maastricht, and written informed consent was
obtained from all subjects.
Pulmonary function testing and blood and sputum 
sampling
Trained lung function technicians measured FEV1 before
and 15 minutes after inhalation of ß-agonist (salbutamol
400 ug) via a metered-dose inhaler, using a spirometer
(Masterlab; Jaeger, Würzburg, Germany), according to
ATS-criteria [2]. Before sputum induction (8:00 to 10:00
A.M.) took place, blood samples were collected in evacu-BMC Pulmonary Medicine 2006, 6:11 http://www.biomedcentral.com/1471-2466/6/11
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ated blood collecting tubes containing ethylenediamine-
tetraacetic acid (EDTA; Sherwood Medical, St. Louis, MO).
Plasma samples were stored at -80°C until analyzed. Spu-
tum was induced according to a procedure reported else-
where [12]. Briefly, subjects inhaled 3% hypertonic saline,
nebulized via an ultrasonic nebulizer (NEB2000; TEFA-
Portanje, Woerden, The Netherlands) during three 7-
minute periods. To minimize saliva contamination, sub-
jects were instructed to mouthwash thoroughly with
saline solution before expectoration. The collected spu-
tum was pooled and kept at 4°C for not more than 2
hours prior to further processing. The volume of the
pooled sputum (without selection of sputum plugs) was
recorded, and an equal volume of 0.2% dithiothreitol
(DTT; Sputolysin; Calbiochem, La Jolla, CA) was added.
The samples were then mixed gently by a vortex mixer and
incubated for 20 minutes at room temperature to ensure
complete homogenization. Cell-free supernatants were
frozen at -80°C until subsequent analysis. The total cell
count and cell viability were assessed using a standard
hemocytometer (Coulter Z1; Coulter Electronics,
Mijdrecht, The Netherlands) and by trypan blue exclu-
sion, respectively. Cytospins were stained according to the
May-Grünwald-Giemsa method. An observer who was
blinded to the clinical characteristics carried out the differ-
ential cell counts, counting 500 nucleated cells. The num-
bers of squamous cells were substracted, and the
differential cell counts were expressed as corrected per-
centages. A sample was considered adequate if the slides
contained 15% or less squamous epithelial cells.
Measurements of inflammatory mediators in sputum and 
plasma
sTNF-R were measured in sputum supernatant and
plasma using specific sandwich enzyme-linked immuno-
sorbent assay (ELISA) as described earlier [20,21], which
were not affected by presence of TNF-α [22], indicating
measurement of total amounts of sTNF-R55 and sTNF-
R75 (free and bound to TNF-α). Total TNF-α (free TNF-α
and TNF-α bound to sTNF-R) was determined using a
commercially available ELISA (HyCult Biotechnology BV,
Uden, The Netherlands). IL-8 and LBP levels were deter-
mined using specific sandwich ELISA as described previ-
ously [19,23,24]. The lower detection limit was 60pg/ml
for sTNF-R55, 30pg/ml for sTNF-R75, 20pg/ml for total
TNF-α, 8 pg/ml for IL-8 and 1ng/ml for LBP. The presence
of DTT resulted in less than 5% inhibition of the detection
of sTNF-R55, IL-8 and LBP and less than 10% inhibition
in case of sTNF-R75 and total TNF-a fraction, indicating
that DTT has little or no effect on the assays used in this
study (data not shown).
Statistical analysis
Results are presented as mean ± SD for normally distrib-
uted variables and median (range) otherwise. Crossec-
tional data analysis was performed on the four diagnostic
categories: COPD, asthma, chronic bronchitis and
'healthy smokers'. Cell patterns and inflammatory media-
tors in induced sputum were analysed, and compared
with inflammatory mediators in blood samples. Cut-off
point for sputum eosinophilia was ≥ 3% [22]. Patterns of
inflammatory markers per diagnosis and clinical factors
associated with eosinophilia were analyzed in an adjusted
backward regression model, the differences expressed in
odds ratios (OR) with 95% confidence intervals. A p value
of less than 0.05 denotes the presence of a significant sta-
tistical difference. (Statistical Package for the Social Sci-
ences, version 11.0 for Windows; SPSS Inc., Chicago, IL).
Results
Table 1 shows the population characteristics, indicating
moderate obstruction (average FEV1 post BD 59% pre-
dicted; GOLD 2) and highest level of packyears in patients
with COPD, while asthmatics have fewer packyears and
clinically relevant reversibility. Healthy smokers and
chronic bronchitis (GOLD 0) patients express normal
lung function despite considerable packyears, while
females are overrepresented among healthy smokers,
especially compared to COPD. No significant differences
with regard to age appear between diagnosis groups.
Table 1: Population characteristics. Figures are means (SD).
COPD n = 17 Asthma n = 11 CB n = 14 HS n = 17
Age (range) 61.4 (41–74) 57.6 (36–73) 53.9 (34–72) 54.6 (42–64)
Gender (f/m) 2/15* 3/8 5/9 11/6*
Smoking status (former/
current)
6/11 5/6 4/10 7/10
Packyears 48.4* (29) 23.1* (20) 33.5 (18) 32.3 (13)
FEV1/FVC postBD 0.56 (0.13)* 0.70 (0.17) 0.73 (0.2) 0.77 (0.22)*
FEV1 postBD (%pred) 59.0* (17) 82.1 (17) 100.7* (17) 103.9* (19)
BD-Reversibility (Δ FEV1 
%pred)
3.5 (9) 12.1* (7) 4.5 (5) 4.9 (4)
*:p < 0.05 using ANOVA analysis.
CB = chronic bronchitis; HS = healthy smokersBMC Pulmonary Medicine 2006, 6:11 http://www.biomedcentral.com/1471-2466/6/11
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In table 2 the inflammatory patterns in different diagnosis
groups are presented. Univariately, COPD was associated
with sputum neutrophilia (OR 1.09 [1.04–1.15]), ele-
vated IL-8 (OR 1.4 [1.1–1.7]), sTNF-R55 (OR 1.005 [1.0–
1.01]) and sTNF-R75 (OR 1.005 [1.0–1.01]) in sputum,
and raised levels of IL-8 (OR 2.5 [1.01–6.0]), sTNF-R55
(OR 7.6 [1.6–35.1]), sTNF-R75 (OR 10.2 [2.2–47.8]) and
LBP (OR 1.1 [1.04–1.25]) in plasma,. Asthma patients
showed a positive association with sputum eosinophils
(OR 1.3 [1.05–1.5]), and inversely with sputum neu-
trophils OR 0.96 [0.9–0.99]), while patients with chronic
bronchitis (GOLD 0) showed raised levels of lymphocytes
(OR 1.5 [1.1–1.9]) in sputum, and significantly lower lev-
els of sTNF-R55 (OR 0.1 [0.02–0.7]) and sTNF-R-75 in
plasma (OR 0.1 [0.2–0.8]). Healthy smokers showed a
lowered LBP (OR 0.8 [0.7–0.95]) in plasma, but no other
significant relations. In table 3 these (positive or negative)
univariate patterns of inflammation are indicated by +
and -, while ++ and – indicate multivariate patterns of
(positive or negative) significant relations.
Multivariate associations
Multivariately, COPD remained significantly associated
with sTNF-R55 in sputum (OR 1.01 [1.001–1.01]) and
raised plasma-LBP (OR 1.2 [1.04–1.37]), while HS
expressed significantly lowered plasma-LBP (OR 0.8
[0.72–0.95]) by contrast (see Table 3). Asthma was char-
acterized by higher sputum eosinophilic counts (OR 1.3
[1.05–1.54]), while CB (GOLD 0) showed a significantly
higher proportion of lymphocytic counts in sputum (OR
1.5 [1.12–1.9]).
Clinically, sputum eosinophilia (≥ 3%) [22] was the only
variable significantly associated with reversibility (OR 1.2
[1.04–1.36]) after adjusting for smoking, lung function,
age, gender and allergy in the backward regression model.
Figure 1 illustrates that sputum eosinophilia occurs across
the spectrum of respiratory disease, independent from
degree of obstruction; post-bronchodilator FEV1s are
between 4–0110% of predicted. The independent rela-
tionship between reversibility and sputum eosinophilia
was somewhat stronger when choosing the more recently
proposed higher cut-off point of 4.6% [14]: OR 1.3 [1.0–
81.53].
Discussion
In this study we demonstrate that distinct inflammatory
patterns in sputum and blood are discernable in clinical
diagnosis groups of respiratory disease in smokers with
airway complaints. Univariately, COPD was associated
with sputum neutrophilia, and raised levels of IL-8, sTNF
R55 and sTNF R75 in both sputum and plasma, and an
increased level of plasma LBP. By contrast, chronic bron-
chitics (GOLD 0) were associated with raised lymphocytes
and lowered sTNF R55 and sTNF R75 plasma-levels.
'Healthy smokers' showed a lowered plasma-LBP level,
while asthma patients showed a pattern of lowered neu-
trophils but high eosinophils. Multivariately, COPD
remained associated with raised sputum-sTNF R55 and
plasma-LBP, in contrast with a significantly and inde-
pendently lowered plasma-LBP in 'healthy smokers'. In
asthma patients, only the high level of sputum eosi-
nophilic inflammation remained independently associ-
ated, which underlines the difference between the sputum
and plasma compartments in differentiating disease.
Chronic bronchitics (GOLD 0) retained a relative pre-
dominance of lymphocytic inflammation in plasma com-
pared to the other clinical diagnosis groups, which could
Table 2: Patterns of inflammatory markers within clinical diagnosis groups. Results are expressed in means (SD).
Compartment Inflammatory markers COPD Asthma CB HS
Sputum cell counts Volume (ml) 6.7 (0.86) 6.9 (0.95) 6.8 (0.93) 3.4 (0.42)
Total counts (106 
cells/ml)
4.3 (0.80) 2.3 (0.91) 2.0 (0.5) 4.0 (0.99)
Neutrophils (%) 81.3* (12.2) 49.0* (25.2) 56.6 (23.2) 62.4 (16.5)
Eosinophils (%) 1.8 (3.7) 20.2* (30.0) 1.3 (1.5) 0.8 (1.1)
Lymphocytes (%) 0.7 (1.2) 1.8 (2.7) 3.4* (3.4) 0.9 (0.8)
Macrophages (%) 16.8* (10.5) 29.1 (24.0) 38.6 (21.9) 35.9 (15.6)
Sputum mediators sTNF-R55 (pg/ml) 658.2* (785.0) 64.4 (14.6) 97.2 (72.7) 169.2 (135.5)
sTNF R-75 (pg/ml) 222.7* (289.3) 64.3 (53.9) 87.6 (68.1) 84.6 (68.8)
LBP (ng/ml) 10.1 (11.2) 9.3 (6.3) 7.9 (8.3) 5.3 (5.7)
IL-8 (ng/ml) 5.5* (3.9) 2.6 (3.2) 2.7 (1.7) 2.4 (1.5)
Plasma mediators sTNF-R55 (ng/ml) 2.0* (0.5) 1.6 (0.4) 1.5* (0.3) 1.8 (0.4)
sTNF-R75 (ng/ml) 2.0* (0.4) 1.7 (0.5) 1.4* (0.3) 1.5 (0.4)
LBP (μg/ml) 28.2* (11.2) 20.0 (4.7) 22.8 (6.5) 17.6* (4.5)
IL-8 (pg/ml) 7.7* (1.3) 7.1 (0.3) 7.2 (0.6) 7 (0.0)
(*indicates statistical difference from total, p < 0.05, using univariate regression analysis) CB = chronic bronchitis; HS = healthy smokersBMC Pulmonary Medicine 2006, 6:11 http://www.biomedcentral.com/1471-2466/6/11
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point at a subpopulation of T cells in this phenotype. The
considerably raised sputum-sTNF R55 and R75 in COPD-
patients is in line with earlier studies of inflammation
[10,14], pointing at structural changes in the airway wall
as a result of prolonged and ongoing smoking-induced
inflammation. Interestingly, the high levels of plasma-
LBP but not in sputum of COPD-patients suggests a blood
born systemic component, which may open a possibility
for disease differentiation. By contrast, the lowered
plasma-LBP in 'healthy smokers' is a new finding that war-
rants further investigation, possibly pointing at genetic
differences in the inflammatory cascade. The clear distinc-
tion in inflammatory patterns between 'at risk' (GOLD 0)
and COPD patients is an intriguing finding, which con-
firms earlier findings from the longitudinal Copenhagen
City Heart Study, in which a gradual development from
Table 3: Univariate and multivariate relations between inflammatory markers in sputum and plasma and clinical diagnosis groups.
Compartment Inflammatory markers COPD Asthma CB HS
Sputum cell counts Neutrophils (%) + -
Eosinophils (%) +/++
Lymphocytes (%) +/++
Macrophages (%) -
Sputum mediators sTNF-R55 (pg/ml) +/++
sTNF-R75 (pg/ml) +
LBP (ng/ml)
IL-8 (ng/ml) +
Plasma mediators sTNF-R55 (ng/ml) + -
sTNF-R75 (ng/ml) + -
LBP (μg/ml) +/++ -/–
IL-8 (pg/ml) +
(+ indicates positive univariate significance; - indicates significant negative univariate relation; ++ indicates positive multivariate significance; -- 
indicates negative multivariate significance) CB = chronic bronchitis; HS = healthy smokers
Sputum eosinophilia (≥ 3%) occurs in a wide range of patients with airway obstruction (1A) and is associated with bronchodila- tor reversibility (1B) Figure 1
Sputum eosinophilia (≥ 3%) occurs in a wide range of patients with airway obstruction (1A) and is associated with bronchodila-
tor reversibility (1B).BMC Pulmonary Medicine 2006, 6:11 http://www.biomedcentral.com/1471-2466/6/11
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GOLD 0 to GOLD 1 or higher levels of obstructive disease
could not be demonstrated [23]. It now seems justified on
the basis of inflammatory patterns to make a clear distic-
tion between chronic bronchitis (GOLD 0) and 'true
COPD' (i.e. GOLD 1,2,3 and 4).
Furthermore, eosinophilia occurs across the spectrum of
clinical diagnosis groups, remaining associated with
reversibility, in contrast with all other clinical variables. It
seems that the recent ATS/ERS Standards for the diagnosis
and treatment of COPD recommendation to 'treat
patients showing a clinically relevant reversibility as asth-
matics' is in line with these findings [2]. Fabbri and cow-
orkers [14] found that despite fixed airflow obstruction
similar to COPD, a history of asthmatic symptoms
remains closely related to eosinophilic inflammation.
Indeed, they concluded that different inflammatory path-
ways do exist in patients with fixed airway obstruction.
Airway inflammation with eosinophils has been reported
to occur not only in asthma but also in other airway dis-
eases such as chronic cough, allergic rhinitis and COPD
[27]. Sputum eosinophilia has been associated with an
accelerated decline in FEV1 and the development of
COPD [28]. Induced sputum analysis allows detection of
sputum eosinophilia in clinical practice [29], which is
clinically important since it may be linked to corticoster-
oid response in COPD [22,30,31]. By contrast, there is
increasing evidence that an absence of sputum eosi-
nophilia is associated with steroid resistance [32,33]. The
proportion of eosinophilic COPD seems to be limited,
and of debatable clinical relevance: 4 out of 17 (24%)
COPD-diagnoses when using the ≥ 3% cut-off for sputum
eosinophilia, but only 1 out of 17 (6%) when using the
more recently proposed cut-off of 4.6% [14]. In our
chronic bronchitis group, we found only 1 out of 14 (7%)
when using the cut-off of 4.6%, while the group of
'healthy smokers' expressed no eosinophilia.
Through multivariate analysis confounding differences in
baseline were corrected for, and insight was achieved into
the relative importance of each variable; most previous
diagnostic studies have not used such statistical tech-
niques. Furthermore, careful age matching during the
recruitment phase resulted in sufficiently comparable
diagnosis groups, since age is known to affect sputum
induction results, especially neutrophilia [15]. Based on
the same reasoning, we excluded the use of inhaled or sys-
temic steroids in the six weeks preceding study, since this
would likely affect levels of inflammatory cells and medi-
ators in sputum and plasma [18].
Conclusion
Based on clinical diagnoses, patterns of inflammatory
markers in blood plasma and sputum were discernable in
clinical diagnosis groups of respiratory disease in smokers
with airway complaints. Multivariately, a smaller set of
variables remained significantly associated, which opens
the possibility to test predictive values of these variables in
larger populations. COPD (GOLD 2) and so-called
'healthy smokers' showed consistent opposite associa-
tions with plasma LBP, while chronic bronchitics (GOLD
0) showed relatively predominant lymphocytic inflam-
mation compared to other diagnosis groups. Eosinophilia
remained significantly associated with reversibility across
the spectrum of respiratory disease in smokers with airway
complaints, while other clinical characteristics were not.
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